Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.9 Million EUR | -48.29% |
| 2022 | -6 Million EUR | 95.15% |
| 2021 | -123.83 Million EUR | -53.34% |
| 2020 | -80.76 Million EUR | -3043.15% |
| 2019 | 2.74 Million EUR | 124.97% |
| 2018 | -10.99 Million EUR | -127.02% |
| 2017 | -4.84 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -9.33 Million EUR | -4.76% |
| 2024 Q2 | -14.98 Million EUR | -60.57% |
| 2023 Q1 | -21.07 Million EUR | -250.82% |
| 2023 Q3 | -296 Thousand EUR | 92.35% |
| 2023 Q4 | -8.9 Million EUR | -2908.78% |
| 2023 Q2 | -3.87 Million EUR | 81.63% |
| 2023 FY | -8.9 Million EUR | -48.29% |
| 2022 Q1 | -70.97 Million EUR | 42.69% |
| 2022 FY | -6 Million EUR | 95.15% |
| 2022 Q4 | -6 Million EUR | 92.26% |
| 2022 Q3 | -77.63 Million EUR | -22.6% |
| 2022 Q2 | -63.32 Million EUR | 10.78% |
| 2021 Q4 | -123.83 Million EUR | 0.0% |
| 2021 FY | -123.83 Million EUR | -53.34% |
| 2021 Q2 | -67.33 Million EUR | 9.72% |
| 2021 Q1 | -74.58 Million EUR | 7.65% |
| 2020 Q1 | 5.85 Million EUR | 113.37% |
| 2020 Q4 | -80.76 Million EUR | 0.58% |
| 2020 Q3 | -81.23 Million EUR | -486.05% |
| 2020 Q2 | -13.86 Million EUR | -336.74% |
| 2020 FY | -80.76 Million EUR | -3043.15% |
| 2019 Q1 | 16.8 Million EUR | 0.0% |
| 2019 Q4 | 2.74 Million EUR | 14.14% |
| 2019 Q3 | 2.4 Million EUR | 0.0% |
| 2019 FY | 2.74 Million EUR | 124.97% |
| 2018 FY | -10.99 Million EUR | -127.02% |
| 2017 FY | -4.84 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 445.06% |
| AngioDynamics, Inc. | -70.14 Million USD | 87.303% |
| AtriCure, Inc. | -9.81 Million USD | 9.271% |
| Avinger, Inc. | 10.12 Million USD | 188.004% |
| Azenta, Inc. | -618.47 Million USD | 98.56% |
| BioLife Solutions, Inc. | 7.25 Million USD | 222.791% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 100.364% |
| Daxor Corporation | 755.65 Thousand USD | 1278.574% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | -505.85% |
| Femasys Inc. | -15.01 Million USD | 40.687% |
| GlucoTrack, Inc. | -4.29 Million USD | -107.309% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 123.138% |
| Hologic, Inc. | 374.4 Million USD | 102.379% |
| ICU Medical, Inc. | 1.45 Billion USD | 100.614% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 99.665% |
| KORU Medical Systems, Inc. | -7.03 Million USD | -26.557% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | -72.13% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -107.723% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -107.723% |
| Masimo Corporation | 804 Million USD | 101.108% |
| Microbot Medical Inc. | -2.28 Million USD | -289.589% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 7.188% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 102.947% |
| Nephros, Inc. | -2.47 Million USD | -260.421% |
| NovoCure Limited | 355.42 Million USD | 102.506% |
| NEXGEL, Inc. | 98 Thousand USD | 9187.755% |
| NEXGEL, Inc. | 98 Thousand USD | 9187.755% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 115.081% |
| OraSure Technologies, Inc. | -276.9 Million USD | 96.784% |
| Pro-Dex, Inc. | 10.91 Million USD | 181.587% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 74.714% |
| Predictive Oncology Inc. | -5.87 Million USD | -51.673% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 394.007% |
| QuidelOrtho Corporation | 2.49 Billion USD | 100.357% |
| Repligen Corporation | -39.51 Million USD | 77.464% |
| Sanara MedTech Inc. | 6.64 Million USD | 234.028% |
| STAAR Surgical Company | -147.2 Million USD | 93.95% |
| Sharps Technology, Inc. | -3.01 Million USD | -195.595% |
| Utah Medical Products, Inc. | -92.52 Million USD | 90.375% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 100.453% |
| Jin Medical International Ltd. | -2.81 Million USD | -216.207% |